SAN DIEGO, June 24, 2011 /PRNewswire/ --Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced results from a retrospective analysis of more than 778,000 ...
PHILADELPHIA--Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced new clinical data from the European Exenatide (EUREXA) study that showed treatment with BYETTA® (exenatide) injection resulted ...
SAN DIEGO and INDIANAPOLIS, Oct. 30, 2009 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced ...
SAN DIEGO and INDIANAPOLIS, Dec. 8 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced that ...
Eli Lilly and Co. could face a delay on the highly anticipated weekly version of its diabetes drug, Byetta. Data for a once-weekly version of Byetta did not adequately show that batches of ...
Minor Label Changes and Approval of Once Weekly Version of Drug Are Anticipated The increasing incidence of obesity has ushered in a ripe market for type 2 diabetes drugs. The commercial landscape is ...
Novo Nordisk's (NVO) new type-2 diabetes drug Victoza is rapidly gaining market share in the all-important U.S. market. The Danish drug maker's early commercial success with its subcutaneous "GLP-1" ...
Novo Nordisk's (NVO) new type-2 diabetes drug Victoza is rapidly gaining market share in the all-important U.S. market. The Danish drug maker's early commercial success with its subcutaneous "GLP-1" ...
Lilly will transition diabetes drug to Amylin for global development and commercialization. Lilly and Amylin inked a deal with $250 million up front that will formally end their exenatide alliance and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback